ISIS

3 Trends That Could Define Drug Discovery in 2014

moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]

Thursday January 23, 2014, Today Stock Market …

NEW! Download all of 2013 Performance: Click to Download!Stock Market Open: 09:30 AM ESTThe Dow opens – 131 and our open trade equity melts. (click to enlarge)EXK (click to enlarge)1 hour in (click to enlarge)INSY (click to enlarge)Close: Dow closes – 175.  This is what we closed out:BBRY +6750,  ATHN -1640, ADEP -663, CRUS -1136, DL +1067, ISIS +756, INSY […]

iCo Therapeutics Announces Positive iCo-007 Phase 2 Clinical Update – Provides Additional Guidance on Study Timelines and Further Updates –

[at noodls] – January 3, 2013, Vancouver, Canada – iCo Therapeutics Inc. (iCo or the Company) (TSX-V: ICO), today announced that at the midpoint of its Phase 2 iDEAL study for the treatment of … moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to […]

Genzyme and Isis Provide Update on CHMP Opinion on KYNAMROâ„¢ (mipomersen)

[at noodls] – )–Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European … moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboardSee who Isis is hiring next, click here to view […]

PropThink: Safety Concerns with Kynamro Battering ISIS Ahead of Advisory Panel Vote

[ACN Newswire] – By Jake KingThe FDA has raised safety concerns about tumors spotted in patients treated with the developmental LDL-lowering therapy, Kynamro. The drug is under review after a New Drug Application was accepted … moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboard […]

Regulus Announces Pricing of Initial Public Offering

[at noodls] – LA JOLLA, CA, October 4, 2012 – Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today … moreView todays social media effects on ISISView the latest stocks trending across Twitter. Click to view dashboard […]